{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12"],"submitter":["Nie K"],"pubmed_abstract":["<h4>Objective</h4>To study the efficacy and toxicity of irinotecan combined with oxaliplatin and S-1 in patients with metastatic pancreatic adenocarcinoma.<h4>Patients and methods</h4>Previously untreated patients with cytologically or histologically confirmed metastatic pancreatic adenocarcinoma underwent a treatment regimen consisting of an intravenous infusion of irinotecan 165 mg/m<sup>2</sup> and oxaliplatin 85 mg/m<sup>2</sup> on day 1, and oral S-1 40 mg/m<sup>2</sup> twice daily on days 1-14, repeating the regimen every 21 days until one of the following occurred: disease progression, intolerable toxicity, or patient death. The primary endpoint was overall survival (OS), and the secondary endpoints were progression-free survival (PFS), response rate, toxicity, and quality of life. "],"journal":["Therapeutic advances in medical oncology"],"pagination":["1758835920970843"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7675906"],"repository":["biostudies-literature"],"pubmed_title":["Irinotecan combined with oxaliplatin and S-1 in patients with metastatic pancreatic adenocarcinoma: a single-arm, three-centre, prospective study."],"pmcid":["PMC7675906"],"pubmed_authors":["Li H","You Y","Zhang Z","Guo X","Nie K","Zhang L","Ji Y","Zhang C"],"additional_accession":[]},"is_claimable":false,"name":"Irinotecan combined with oxaliplatin and S-1 in patients with metastatic pancreatic adenocarcinoma: a single-arm, three-centre, prospective study.","description":"<h4>Objective</h4>To study the efficacy and toxicity of irinotecan combined with oxaliplatin and S-1 in patients with metastatic pancreatic adenocarcinoma.<h4>Patients and methods</h4>Previously untreated patients with cytologically or histologically confirmed metastatic pancreatic adenocarcinoma underwent a treatment regimen consisting of an intravenous infusion of irinotecan 165 mg/m<sup>2</sup> and oxaliplatin 85 mg/m<sup>2</sup> on day 1, and oral S-1 40 mg/m<sup>2</sup> twice daily on days 1-14, repeating the regimen every 21 days until one of the following occurred: disease progression, intolerable toxicity, or patient death. The primary endpoint was overall survival (OS), and the secondary endpoints were progression-free survival (PFS), response rate, toxicity, and quality of life. ","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020","modification":"2025-04-04T10:55:33.78Z","creation":"2021-02-21T04:09:14Z"},"accession":"S-EPMC7675906","cross_references":{"pubmed":["33240399"],"doi":["10.1177/1758835920970843"]}}